1. Hederacolchiside C inhibits Enterovirus 71 propagation through activating innate immunity
- Author
-
Ikhlas A. Khan, Yan-Er Wang, Yanli Liu, Shilin Yang, Kun-Ping Li, Naixin Kang, Jianping Zhao, and Qiongming Xu
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.drug_class ,030106 microbiology ,Biology ,Virus Replication ,Antiviral mechanism ,Antiviral Agents ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Line, Tumor ,medicine ,Enterovirus 71 ,Animals ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Oleanolic Acid ,Pathogen ,Innate immune system ,Dose-Response Relationship, Drug ,Effector ,Ribavirin ,Saponins ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,Virology ,Immunity, Innate ,Enterovirus A, Human ,Disease Models, Animal ,Infectious Diseases ,chemistry ,Host-Pathogen Interactions ,Pulsatilla ,Antiviral drug ,Hand, Foot and Mouth Disease ,IRF3 - Abstract
Enterovirus 71 (EV71), a newly emerging life-threatening pathogen induces hand-foot-mouth disease (HFMD), no effective vaccines or specific anti-viral treatments are currently available. In this study, the activity of hederacolchiside C (HSC) against EV71 was investigated, and the antiviral mechanism was explored. HSC displayed apparent antiviral activity in EV71-infected cells probably through activating the host innate immunity. Comparing with EV71-infected group at 24 hpi, the group pretreated with HSC dramatically increased the expression of MAVS, p-IRF3, IRF3 and IFN-β, the innate immune effectors related to innate immunity. In addition, HSC displayed stronger antiviral activity in EV71-infected suckling mice in comparison with Ribavirin, a broad-spectrum antiviral drug. The results suggest that HSC could have potential as a pharmaceutical drug for HFMD.
- Published
- 2019